Last reviewed · How we verify
NCT04894123
Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients
Phase 2 trial testing Trifluridine/Tipiracil in Colorectal Adenocarcinoma in 1 participant. Terminated before completion.
13 February 2023
Quick facts
| Lead sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 7 February 2022 |
| Primary completion | 13 February 2023 |
| Estimated completion | 13 February 2023 |
| Sites | 11 locations across France |
Drugs / interventions tested
- Trifluridine/Tipiracil
- Oxaliplatin (Oxaliplatin) — full drug profile →
Conditions studied
- Colorectal Adenocarcinoma — all drugs for Colorectal Adenocarcinoma →
- Oesogastric — all drugs for Oesogastric →
Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Who can join
18 and older, any sex, with Colorectal Adenocarcinoma or Oesogastric. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the incidence of cardiovascular events in patients with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin after an episode of cardiac angina-related thoracic pain due to fluoropyrimidines in the adjuvant or metastatic setting .
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04894123
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Trifluridine/Tipiracil
Trials testing the same drug.
- NCT06195111 — A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study) · not yet recruiting
- NCT05965531 — Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy · Phase 2 · recruiting
- NCT05970705 — Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC · Phase 2 · recruiting
- NCT05223673 — Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single A · Phase 3 · terminated
- NCT05077839 — Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC · Phase 2 · unknown
Other recruiting trials for Colorectal Adenocarcinoma
Currently open trials in the same condition.
- NCT06955767 — Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes · NA · recruiting
- NCT07407465 — Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal · Phase 2 · recruiting
- NCT06951503 — AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer · Phase 3 · recruiting
- NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
- NCT06225011 — Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer · Phase 1 · recruiting
Other GERCOR - Multidisciplinary Oncology Cooperative Group trials
Trials by the same sponsor.
- NCT05787197 — ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases · recruiting
- NCT06059495 — Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study · Phase 2 · recruiting
- NCT04935853 — Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study · recruiting
- NCT03704480 — Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. · Phase 2 · active not recruiting
- NCT03519295 — A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04894123 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GERCOR - Multidisciplinary Oncology Cooperative Group
- Last refreshed: 18 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04894123.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing